Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
ALKS reports weaker-than-expected third-quarter 2024 results. Net sales of proprietary products increase year over year.
Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript
Alkermes plc (NASDAQ:ALKS ) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Investor Relations and Corporate Affairs Richard Pops - CEO Todd Nichols - Chief Commercial Officer Blair Jackson - Chief Operating Officer. Conference Call Participants Joseph Thome - TD Cowen Umer Raffat - Evercore Paul Matteis - Stifel Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler Joel Beatty - Baird Uy Ear - Mizuho Securities Jessica Fye - JPMorgan Jason Gerberry - Bank of America Marc Goodman - Leerink Partners Ash Fermot - UBS Douglas Tsao - H.C.
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates
Alkermes (ALKS) came out with quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.64 per share a year ago.
Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Besides Wall Street's top -and-bottom-line estimates for Alkermes (ALKS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Here's Why Alkermes (ALKS) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Alkermes (ALKS) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Alkermes (ALKS) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Alkermes (ALKS) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Alkermes (ALKS) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680
Alkermes' (ALKS) phase II Vibrance-2 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with narcolepsy type 2.
